Lowest Price Guaranteed From USD 4,799
Published
February 2023
Pages
278
View Count
27605
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global DNA encoded library market is estimated to be worth USD 840 million in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period 2023-2035. Over the years, DNA encoded libraries have emerged as a powerful platform for drug discovery, enabling the synthesis and screening of millions of small molecules in a single study. DNA encoded libraries are collections of small molecules attached with DNA tags, which serve as barcodes to identify the molecules. Further, the use of DNA encoded chemical library has gained momentum in recent years due to their ability to accelerate the drug discovery process by reducing the time and cost associated with traditional high-throughput screening methods. Moreover, the increasing demand for innovative therapies to treat complex diseases, such as oncological disorders and neurological disorders, has led to a surge in the development of DNA encoded libraries. Additionally, the growing adoption of DNA encoded chemical library by pharmaceutical and biotechnology companies, academic institutions and contract research organizations has further propelled the market growth of this industry. Driven by the ongoing pace of innovation in this field and sufficient financial support from investors, the DNA encoded library market is likely to witness substantial growth during the forecast period.
The DNA Encoded Library Market: Platforms and Services (2nd Edition) - Distribution by Application Area (Hit Generation / Identification, Hit to Lead, Hit Validation / Optimization and Other Application Areas), Therapeutic Area (Oncological Disorders, Immunological Disorders, Neurological Disorders, Respiratory Disorders, Dermatological Disorders, Cardiovascular Disorders, Infectious Diseases and Other Therapeutic Areas), End-users (Pharma / Biopharma Industry, Academic / Research Institute and Other End-users), Type of Payment Model Employed (Upfront Payment and Milestone Payment) and Key Geographical Regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities for the DNA encoded library companies, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the DNA encoded library market report are briefly discussed below.
DNA encoded libraries (also known as DELs), owing to their advantages over high-throughput screening, have emerged to be a sophisticated combinatorial drug discovery tool for the synthesis and screening of large collections of small molecule compounds. Interestingly, DNA encoded libraries encompassing as high as 40 trillion different molecules has been developed, enabling screening, hit identification and discovery of pharmacological leads, such as macrocycles, natural products and small molecules. Furthermore, single DNA encoded library has proven to be a helpful tool in lead optimization against undruggable and unique targets and accelerating the drug development process.
Moreover, the introduction of automated screening of small organic ligands using DEL technology has enabled the identification of potential lead molecules within a time span of a few days. As a result, a large number of pharmaceutical companies and academic / research institutions are investing in this technology to accelerate the drug discovery process and bring new treatments to patients faster. Furthermore, it has been observed that DNA encoded library is being applied for purposes beyond drug discovery. For instance, a collaboration was established in 2022 between X-Chem and Enko to enhance the Enkompass platform for the development of solutions focused on crop protection.
Competitive Landscape Analysis: DNA Encoded Library Companies
DNA encoded library market landscape features the presence of close to 50 large, mid-sized and small companies offering various services related to DNA encoded libraries for the purpose of drug discovery, including hit identification, hit optimization / validation and lead generation. It is worth highlighting that several big pharma companies are also using DNA encoded libraries for drug discovery. For instance, Amgen uses its DNA encoded library (owned post-acquisition of Nuevolution) for in-house drug development purposes. Other big pharma companies such as GSK, Pfizer, Roche, Novartis, AstraZeneca, Bristol Myers Squibb, Sanofi and Janssen are also using DEL technology either through in-house capability or collaboration with a DEL technology / service provider.
Owing to its access to the largest chemical space available in the market, DNA encoded chemical library platforms are a natural fit for big data analytics and modeling technologies offered by artificial intelligence and machine learning. As a result, some companies have been pursuing this opportunity by integrating artificial intelligence and machine learning in DNA encoded libraries, including Insitro, a leading player in machine learning for drug discovery, which acquired Haystack Sciences in 2020. Insitro made the acquisition to leverage Haystack Sciences DNA sequencing technology to enhance its machine learning based drug discovery capability. Additionally, Google Research also collaborated with X-Chem in 2020 to develop an effective method for finding biologically active molecules using physical and virtual screening. Further, in 2021, Relay Therapeutics acquired ZebiAI for USD 85 million upfront, allowing them to incorporate the machine learning based DNA encoded chemical library technology into their protein targeting platform, Dynamo.
Several stakeholders have been forging alliances with other industry / non-industry players in DNA encoded library market for platform and product licensing, research and development and product development purposes. It is worth highlighting that, since 2010, over 175 strategic partnerships have been inked in the DNA encoded library market. A notable example of partnership inked in 2023 includes research agreement between Orbit Discovery and SanegeneBio to identify and optimize hits focused on the disease-causing gene.
Owing to several advantages of DNA encoded libraries in drug discovery, the stakeholders are also acquiring other industry players specializing in various aspects of DNA encoded library in order to expand their capabilities and to build a comprehensive product / service portfolio. In October 2021, X-Chem acquired Glamorous.AI, a biotechnology firm, to incorporate artificial intelligence in DNA encoded libraries and operate as a one-stop-shop in the DNA encoded library market.
The growing interest in DNA encoded library market can be validated by the fact that in the last two years, close to USD 2.5 billion has been invested by several investors based across the globe, in companies engaged in the development of DNA encoded libraries. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Relay Therapeutics and DiCE Therapeutics are the leading DNA encoded library companies, owing to the secondary offerings received in 2022, respectively.
Interestingly, the patent filing activity in the industry has also witnessed a growth rate of over 20%, in the last decade. Consistent support from the venture capital firms is anticipated to ensure the development of more advanced DNA encoded chemical libraries.
The global DNA encoded library market is estimated to be worth USD 840 million in 2023. Currently, the market is likely to be driven by two business models; the first involves the out-licensing of proprietary DNA encoded library platforms to interested clients and the second involves charging fee-for-service to conduct research using their libraries. As the promise of DNA encoded library-based drug discovery is realized, the business models will become more collaborative in nature. The presence of big pharmaceuticals will play a major role in establishing the confidence of the industry in DEL technology. In late 2021, Amgen moved one of its small molecule drugs AMG 193, identified using Amgen’s proprietary DEL technology, to phase I/II clinical trial. The trial is active and recruiting participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The market size is expected to grow at a CAGR of 16.04% during the forecast period, mainly driven by the number of DNA encoded library discovered small molecule drugs reaching clinical trials.
In the past few years, several well-funded start-ups / small companies, offering DNA encoded library platforms and associated services have been established. Of these, the majority of companies are headquartered in North America and Europe. Consequently, more than 70% of the global market of DNA encoded libraries is anticipated to be captured by players based in North America and Europe, in 2035. These companies will support the drug discovery initiatives of pharmaceutical drug developers, generating revenues through out-licensing or fee-for-service models.
Examples of the key DNA encoded library companies (the complete list of players is available in the full report) include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec and X-Chem. This market report also includes an easily searchable excel database of all the DNA encoded library companies worldwide.
Several recent developments have taken place in the field of DNA encoded library market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table:
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the report includes:
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the DNA encoded library market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035, Additionally, historical trend of the market has also been presented for the time period, 2017-2022. Further, our year-wise projections of the current and forecasted opportunity have been segmented based on relevant parameters, such as application areas (hit generation / identification, hit to lead, hit validation / optimization and other application areas), therapeutic area (oncological disorders, immunological disorders, neurological disorders, respiratory disorders, dermatological disorders, cardiovascular disorders, infectious diseases and other therapeutic areas), end-user (pharma / biopharma industry, academic / research institute and other end-users), type of payment method (upfront payment and milestone payment) and key geographical regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.
The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report also features detailed transcripts of interviews held with various industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Answer: A DNA encoded library is a collection of small molecules attached with DNA-tags that have unique information about the identity and the structure of each library member. DNA encoded library platform enables efficient synthesis, handling and interrogation of vast number of chemically synthesized drug-like compounds.
Answer: The high-throughput screening capability of DNA encoded libraries allows for the rapid identification of potential drug candidates, making them particularly useful in the early stages of drug discovery when a large number of compounds need to be tested.
Answer: The development of a DNA encoded library is based on tagging small molecules / organic leads with short DNA sequences and then utilizing combinatorial chemistry to generate a huge number of structurally and functionally varied compounds with unique DNA tags.
Answer: Presently, DNA-recorded synthesis formats are widely used to encode information in DNA, which involve a series of reactions in the solution phase. Apart from this, encoding by ligation of single-stranded oligonucleotide, encoding by ligation of double-stranded oligonucleotide and encoding by polymerase-catalysed fill-in reaction are some of the encoding strategies used for encoding the information in DNA.
Answer: DNA encoded libraries have transformed drug discovery by providing a diverse range of compounds that can be screened for potential drugs. This method is faster and more efficient than traditional screening methods and can identify novel compounds that may have been missed otherwise. It also provides valuable information on the structure and interactions of lead molecules.
Answer: DNA encoded library technology is very helpful during the early stages of drug discovery since it requires less investment, time and storage space to identify target compounds. Apart from these, there are several other advantages as well, such as cost-effective process, rapid screening of large number of leads and hit identification against undruggable targets.
Answer: Presently, close to 50 companies are offering services related to DNA encoded libraries for the purpose of drug discovery. Majority of the encoded libraries are designed to identify leads against protein pump inhibitors, which are otherwise difficult to screen using traditional libraries.
Answer: The DNA encoded library market is likely to be driven by two business models; the first involves out-licensing of proprietary library platforms to interested clients and the second involves charging fee-for-service to conduct research using their libraries.
Answer: A total of 403 patents have been filed in the field of DNA encoded libraries. Of these, 277 patents are patent applications, while 114 are granted patents. Of the total granted patents, around 65% patents have been filed in the US.
Answer: Examples of key players engaged in DNA encoded library market (which have also been captured in this report) include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec and X-Chem.
Answer: In terms of type of therapeutic area, oncological disorders currently account for the largest share (35%) of the global DNA encoded library market. Further, in terms of application area, hit generation / identification is likely to capture over 60% of the current and future market.
Answer: Presently, the DNA encoded library market is dominated by North America, capturing around 45% of the overall market size.
Answer: The DNA encoded library market is projected to grow at an annualized rate (CAGR) of ~17%, during the forecast period 2023-2035.
Contents
1. PREFACE
1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization
3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
3.5. Future Perspectives and Opportunity Areas
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)
5. BUSINESS MODEL ANALYSIS
5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks
12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
15.7. Anonymous
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Business Model Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Construction Process of a DNA Encoded Library
Figure 3.4 Encoding Strategies for Constructing DNA Encoded Libraries
Figure 3.5 Historical Evolution of DNA Encoded Libraries
Figure 3.6 Comparison of Traditional Libraries and DNA Encoded Libraries
Figure 3.7 Key Advantages of DNA Encoded Libraries
Figure 3.8 Challenges and Limitations Associated with DNA Encoded Libraries
Figure 4.1 DNA Encoded Libraries: Distribution by Year of Establishment
Figure 4.2 DNA Encoded Libraries: Distribution by Company Size
Figure 4.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Figure 4.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Figure 4.7 DNA Encoded Libraries: Distribution by Library Size
Figure 4.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Figure 4.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Figure 4.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Figure 4.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Figure 4.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Figure 4.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Figure 4.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Figure 4.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Figure 4.16 DNA Encoded Libraries: Distribution by End-user(s)
Figure 5.1 DNA Encoded Libraries: Distribution by Operational Model
Figure 5.2 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Figure 5.3 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Figure 5.4 DNA Encoded Libraries: Distribution by Business Model
Figure 5.5 DNA Encoded Libraries: Distribution by Service Centric Model
Figure 5.6 DNA Encoded Libraries: Distribution by Product Centric Model
Figure 6.1 Company Competitiveness Analysis: DNA Encoded Library Companies based in North America
Figure 6.2 Company Competitiveness Analysis: DNA Encoded Library Companies based in Europe
Figure 6.3 Company Competitiveness Analysis: DNA Encoded Library Companies based in Asia-Pacific
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Figure 8.5 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8 Partnerships and Collaborations: Distribution by Partner Company Size
Figure 8.9 Most Active Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: International and Local Agreements
Figure 8.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Figure 9.2 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Figure 9.3 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Figure 9.4 Funding and Investment : Distribution of Instances by Type of Funding
Figure 9.5 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 9.8 Most Active Investors: Distribution by Number of Instances
Figure 9.9 Funding and Investment: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Figure 9.10 Funding and Investment: Distribution of Number of Instances by Geography (Country-wise)
Figure 9.11 Funding and Investment: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Figure 10.3 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Figure 10.4 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Figure 10.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Figure 10.7 Patent Analysis: Distribution by CPC Symbols
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Patent Analysis: Distribution by Relative Patent Valuation
Figure 11.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharma Companies
Figure 11.2 Spider Web Analysis: AbbVie
Figure 11.3 Spider Web Analysis: Amgen
Figure 11.4 Spider Web Analysis: AstraZeneca
Figure 11.5 Spider Web Analysis: Bayer
Figure 11.6 Spider Web Analysis: Boehringer Ingelheim
Figure 11.7 Spider Web Analysis: Eli Lilly
Figure 11.8 Spider Web Analysis: GlaxoSmithKline (GSK)
Figure 11.9 Spider Web Analysis: Johnson & Johnson
Figure 11.10 Spider Web Analysis: Merck
Figure 11.11 Spider Web Analysis: Novartis
Figure 11.12 Spider Web Analysis: Pfizer
Figure 11.13 Spider Web Analysis: Sanofi
Figure 12.1 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Figure 12.2 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Figure 12.3 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Figure 12.4 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Figure 12.5 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Figure 12.6 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Figure 12.7 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035 (USD Billion)
Figure 13.4 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Figure 13.5 DNA Encoded Library Market for Hit Generation / Identification, 2023-2035 (USD Million)
Figure 13.6 DNA Encoded Library Market for Hit to Lead, 2023-2035(USD Million)
Figure 13.7 DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035 (USD Million)
Figure 13.8 DNA Encoded Library Market for Other Application Areas, 2023-2035 (USD Million)
Figure 13.9 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 13.10 DNA Encoded Library Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 13.11 DNA Encoded Library Market for Immunological Disorders, 2023-2035 (USD Million)
Figure 13.12 DNA Encoded Library Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 13.13 DNA Encoded Library Market for Respiratory Disorders, 2023-2035 (USD Million)
Figure 13.14 DNA Encoded Library Market for Dermatological Disorders, 2023-2035 (USD Million)
Figure 13.15 DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 13.16 DNA Encoded Library Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 13.17 DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035 (USD Million)
Figure 13.18 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Figure 13.19 DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035 (USD Million)
Figure 13.20 DNA Encoded Library Market for Academic / Research Institute, 2023-2035 (USD Million)
Figure 13.21 DNA Encoded Library Market for Other End-users, 2023-2035 (USD Million)
Figure 13.22 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Figure 13.23 DNA Encoded Library Market: Upfront Payments, 2023-2035 (USD Million)
Figure 13.24 DNA Encoded Library Market: Milestone Payments, 2023-2035 (USD Million)
Figure 10.25 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 13.26 DNA Encoded Library Market in the US, 2023-2035 (USD Million)
Figure 13.27 DNA Encoded Library Market in Europe, 2023-2035 (USD Million)
Figure 13.28 DNA Encoded Library Market in Denmark, 2023-2035 (USD Million)
Figure 13.29 DNA Encoded Library Market in Germany, 2023-2035 (USD Million)
Figure 10.30 DNA Encoded Library Market in UK, 2023-2035 (USD Million)
Figure 13.31 DNA Encoded Library Market in Switzerland, 2023-2035 (USD Million)
Figure 13.32 DNA Encoded Library Market in France, 2023-2035 (USD Million)
Figure 13.33 DNA Encoded Library Market in Rest of the Europe, 2023-2035 (USD Million)
Figure 13.34 DNA Encoded Library Market in China, 2023-2035 (USD Million)
Figure 14.1 Concluding Remarks: Market Landscape
Figure 14.2 Concluding Remarks: Business Model Analysis
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Funding and Investment Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 4.1 DNA Encoded Libraries: List of Service Providers / Platform Providers / In-House Companies
Table 4.2 DNA Encoded Libraries: Information on Library Size, Library Synthesis Method(s) and Library Screening Method(s)
Table 4.3 DNA Encoded Libraries: Information on Type of Product(s) and Service(s) Offered
Table 4.4 DNA Encoded Libraries: Information on Type of Pharmacological Lead(s) and Therapeutic Target(s)
Table 4.5 DNA Encoded Libraries: Information on Therapeutic Area(s) and End-user(s)
Table 5.1 DNA Encoded Libraries: Information on Company Size, Location of Headquarters and Operational Model
Table 5.2 DNA Encoded Libraries: Information on Business Model
Table 7.1 DNA Encoded Libraries: List of Companies Profiled
Table 7.2 AlphaMa: Company Snapshot
Table 7.3 AlphaMa: DNA Encoded Library Platform and Service Portfolio
Table 7.4 AlphaMa: Recent Developments and Future Outlook
Table 7.5 DICE Therapeutics: Company Snapshot
Table 7.6 DICE Therapeutics: DNA Encoded Library Platform and Service Portfolio
Table 7.7 DICE Therapeutics: Recent Developments and Future Outlook
Table 7.8 DyNAbind: Company Snapshot
Table 7.9 DyNAbind: DNA Encoded Library Platform and Service Portfolio
Table 7.10 DyNAbind: Recent Developments and Future Outlook
Table 7.11 HitGen: Company Snapshot
Table 7.12 HitGen: DNA Encoded Library Platform and Service Portfolio
Table 7.13 HitGen: Recent Developments and Future Outlook
Table 7.14 NovAliX: Company Snapshot
Table 7.15 NovAliX: DNA Encoded Library Platform and Service Portfolio
Table 7.16 NovAliX: Recent Developments and Future Outlook
Table 7.17 Vipergen: Company Snapshot
Table 7.18 Vipergen: DNA Encoded Library Platform and Service Portfolio
Table 7.19 Vipergen: Recent Developments and Future Outlook
Table 7.20 WuXi AppTec: Company Snapshot
Table 7.21 WuXi AppTec: DNA Encoded Library Platform and Service Portfolio
Table 7.22 X-Chem: Company Snapshot
Table 7.23 X-Chem: DNA Encoded Library Platform and Service Portfolio
Table 7.24 X-Chem: Recent Developments and Future Outlook
Table 8.1 DNA Encoded Libraries: List of Partnerships and Collaborations, 2010-2023
Table 9.1 DNA Encoded Libraries: List of Funding and Investments, 2018-2023
Table 10.1 Patent Analysis: Top CPC Sections
Table 10.2 Patent Analysis: Top CPC Symbols
Table 10.3 Patent Analysis: Top CPC Codes
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 12.1 DNA Encoded Libraries: List of Supporting Companies / Organizations
Table 12.2 DNA Encoded Libraries: Information on Type of Support Services / Ancillary Tools Offered
Table 13.1 DNA Encoded Libraries: Average Upfront Payment and Average Milestone Payment, 2016-2022 (USD Million)
Table 13.2 Library Licensing Deals: Tranches of Milestone Payments
Table 15.1 Vipergen: Company Key Highlights
Table 15.2 Serengen: Company Key Highlights
Table 15.3 Deluge Biotechnologies: Company Key Highlights
Table 15.4 NovAliX: Company Key Highlights
Table 15.5 Orbit Discovery: Company Key Highlights
Table 16.1 DNA Encoded Libraries: Distribution by Year of Establishment
Table 16.2 DNA Encoded Libraries: Distribution by Company Size
Table 16.3 DNA Encoded Libraries: Distribution by Location of Headquarters (Region-wise)
Table 16.4 DNA Encoded Libraries: Distribution by Location of Headquarters (Country-wise)
Table 16.5 DNA Encoded Libraries: Distribution by Company Size and Location of Headquarters
Table 16.6 DNA Encoded Libraries: Distribution by Type of Company / Organization
Table 16.7 DNA Encoded Libraries: Distribution by Library Size
Table 16.8 DNA Encoded Libraries: Distribution by Library Synthesis Method(s)
Table 16.9 DNA Encoded Libraries: Distribution by Library Screening Method(s)
Table 16.10 DNA Encoded Libraries: Distribution by Type of Product(s) Offered
Table 16.11 DNA Encoded Libraries: Distribution by Type of Library Design Service(s) Offered
Table 16.12 DNA Encoded Libraries: Distribution by Type of Library Screening Service(s) Offered
Table 16.13 DNA Encoded Libraries: Distribution by Type of Pharmacological Lead(s)
Table 16.14 DNA Encoded Libraries: Distribution by Therapeutic Target(s)
Table 16.15 DNA Encoded Libraries: Distribution by Therapeutic Area(s)
Table 16.16 DNA Encoded Libraries: Distribution by End-user(s)
Table 16.17 DNA Encoded Libraries: Distribution by Operational Model
Table 16.18 DNA Encoded Libraries: Distribution by Company Size and Operational Model
Table 16.19 DNA Encoded Libraries: Distribution by Location of Headquarters and Operational Model
Table 16.20 DNA Encoded Libraries: Distribution by Business Model
Table 16.21 DNA Encoded Libraries: Distribution by Service Centric Model
Table 16.22 DNA Encoded Libraries: Distribution by Product Centric Model
Table 16.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023
Table 16.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.26 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2018 and Post-2018
Table 16.27 Partnerships and Collaborations: Distribution by Focus Area
Table 16.28 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.30 Partnerships and Collaborations: Distribution by Partner Company Size
Table 16.31 Most Active Players: Distribution by Number of Partnerships
Table 16.32 Partnerships and Collaborations: International and Local Agreements
Table 16.33 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.34 Funding and Investment: Distribution by Year, Type of Funding and Amount Invested, 2018-2023 (USD Million)
Table 16.35 Funding and Investment: Distribution of Instances by Year of Funding, 2018-2023
Table 16.36 Funding and Investment: Distribution of Amount Invested by Year of Funding, 2018-2023 (USD Million)
Table 16.37 Funding and Investment: Distribution of Instances by Type of Funding
Table 16.38 Funding and Investment: Distribution of Amount Invested by Type of Funding (USD Million)
Table 16.39 Most Active Players: Distribution by Number of Funding Instances
Table 16.40 Most Active Players: Distribution by Amount Raised (USD Million)
Table 16.41 Most Active Investors: Distribution by Number of Instances
Table 16.42 Funding and Investment Analysis: Distribution of Number of Instances and Amount Invested by Geography (Region-wise) (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution of Number of Instances by Geography (Country-wise)
Table 16.44 Funding and Investment Analysis: Summary of Investments by Number of Instances and Amount Invested (USD Million)
Table 16.45 Patent Analysis: Distribution by Type of Patent
Table 16.46 Patent Analysis: Distribution by Patent Publication Year, Pre-2010-2023
Table 16.47 Patent Analysis: Distribution by Patent Application Year, Pre-2010-2022
Table 16.48 Patent Analysis: Distribution by Type of Patent and Publication Year, Pre-2010-2023
Table 16.49 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
Table 16.50 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
Table 16.51 Patent Analysis: Distribution by CPC Symbols
Table 16.52 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.53 Leading Industry Players: Distribution by Number of Patents
Table 16.54 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.55 Leading Individual Assignees: Distribution by Number of Patents
Table 16.56 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Table 16.57 Patent Analysis: Distribution by Patent Age
Table 16.58 Patent Analysis: Distribution by Relative Patent Valuation
Table 16.59 Big Pharma Players: Heat Map Analysis of Top Pharma Companies
Table 16.60 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Year of Establishment
Table 16.61 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size
Table 16.62 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters
Table 16.63 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Company Size and Location of Headquarters
Table 16.64 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Company / Organization
Table 16.65 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Type of Support Services / Ancillary Tools Offered
Table 16.66 DNA Encoded Libraries Supporting Companies / Organizations: Distribution by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
Table 16.67 Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Opportunity, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.68 DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035 (USD Million)
Table 16.69 DNA Encoded Library Market for Hit Generation / Identification, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.70 DNA Encoded Library Market for Hit to Lead, Conservative, Base and Optimistic Scenarios, 2023-2035(USD Million)
Table 16.71 DNA Encoded Library Market for Hit Validation / Optimization, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.72 DNA Encoded Library Market for Other Application Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.73 DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 16.74 DNA Encoded Library Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.75 DNA Encoded Library Market for Immunological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.76 DNA Encoded Library Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.77 DNA Encoded Library Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.78 DNA Encoded Library Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.79 DNA Encoded Library Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.80 DNA Encoded Library Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.81 DNA Encoded Library Market for Other Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.82 DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035 (USD Million)
Table 16.83 DNA Encoded Library Market for Pharma / Biopharma Industry, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.84 DNA Encoded Library Market for Academic / Research Institute, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.85 DNA Encoded Library Market for Other End-users, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.86 DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Million)
Table 16.87 DNA Encoded Library Market: Upfront Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.88 DNA Encoded Library Market: Milestone Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.89 DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 16.90 DNA Encoded Library Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.91 DNA Encoded Library Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.92 DNA Encoded Library Market in Denmark, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.93 DNA Encoded Library Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.94 DNA Encoded Library Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.95 DNA Encoded Library Market in Switzerland, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.96 DNA Encoded Library Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.97 DNA Encoded Library Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 16.98 DNA Encoded Library Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Source 1: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/how-clinical-trials-are-planned-and-organised/how-long-it-takes-for-a-new-drug-to-go-through-clinical-trials
Source 2: https://www.prnewswire.com/news-releases/enko-advances-enkompass-platform-through-dna-encoded-library-technology-enablement-from-x-chem-301567231.html
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES